Switzerland ranks among the world’s leading countries in hip replacements per capita, yet current implants often fail within 10–16 years. In younger and more active patients, revision rates reach up to 33%, largely because existing materials cannot replicate the ultra-low friction and damping properties of natural cartilage, limiting implant longevity and quality of life.
RheoCarti addresses this unmet need with a titanium–hydrogel joint implant, developed at ETH Zurich by Dr. Xiaoyu Du (CEO) and Prof. Stephen Ferguson (Scientific Advisor), with patent pending. Its hydrogel-on-hydrogel articulating surface achieves ultra-low friction and superior shock absorption, closely mimicking native cartilage and offering particular benefits for active patients.
Please check https://rheocarti.com.
RheoCarti addresses this unmet need with a titanium–hydrogel joint implant, developed at ETH Zurich by Dr. Xiaoyu Du (CEO) and Prof. Stephen Ferguson (Scientific Advisor), with patent pending. Its hydrogel-on-hydrogel articulating surface achieves ultra-low friction and superior shock absorption, closely mimicking native cartilage and offering particular benefits for active patients.
Please check https://rheocarti.com.
Location: Switzerland
Total raised: $50.12K
Investors 1
| Date | Name | Website |
| 23.02.2026 | Venture Ki... | venturekic... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.03.2026 | Seed | $50.12K | Venture Ki... |
Mentions in press and media 1
| Date | Title | Description |
| 03.03.2026 | RheoCarti receives CHF 40,000 from Venture Kick to advance veterinary implant toward market entry | What was the first real signal that your solution worked outside the lab or pitch deck, and what did that moment change for you? The real signal came when surgeons and veterinarians held the implant in their hands for the first time. As the... |